Blood Lead Level As Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers

BRCA1 mutations substantially elevate the risks of breast and ovarian cancer. Various modifiers, including environmental factors, can influence cancer risk. Lead, a known carcinogen, has been associated with various cancers, but its impact on BRCA1 carriers remains unexplored. A cohort of 989 BRCA1 mutation carriers underwent genetic testing at the Pomeranian Medical University, Poland. Blood lead levels were measured using inductively coupled plasma mass spectrometry. Each subject was assigned to a category based on their tertile of blood lead. Cox regression analysis was used to assess cancer risk associations. Elevated blood lead levels (>13.6 μg/L) were associated with an increased risk of ovarian cancer (univariable: HR = 3.33; 95% CI: 1.23-9.00; = 0.02; multivariable: HR = 2.10; 95% CI: 0.73-6.01; = 0.17). No significant correlation was found with breast cancer risk. High blood lead levels are associated with increased risk of ovarian cancer in BRCA1 carriers, suggesting priority for preventive salpingo-oophorectomy. Potential risk reduction strategies include detoxification. Validation in diverse populations and exploration of detoxification methods for lowering lead levels are required.

Citing Articles

Persistent Metabolic Changes Are Induced by 24 h Low-Dose Lead (Pb) Exposure in Zebrafish Embryos.

Cooper G, North R, Hunt-Smith T, Larson J, Rennie M, Bailey M Int J Mol Sci. 2025; 26(3).

PMID: 39940818 PMC: 11817773. DOI: 10.3390/ijms26031050.

Association between weight-adjusted-waist index and gynecologic cancers: a population-based study.

Fang L, Li X, Fang Y, Wang Y, Wang R, Xie Y Front Nutr. 2024; 11:1449643.

PMID: 39346649 PMC: 11437532. DOI: 10.3389/fnut.2024.1449643.

Blood molybdenum level as a marker of cancer risk on BRCA1 carriers.

Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P Hered Cancer Clin Pract. 2024; 22(1):19.

PMID: 39300540 PMC: 11411732. DOI: 10.1186/s13053-024-00291-7.

The preventive and carcinogenic effect of metals on cancer: a systematic review.

Khoshakhlagh A, Mohammadzadeh M, Gruszecka-Kosowska A BMC Public Health. 2024; 24(1):2079.

PMID: 39090615 PMC: 11293075. DOI: 10.1186/s12889-024-19585-5.

Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.

Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P Antioxidants (Basel). 2024; 13(7).

PMID: 39061909 PMC: 11273827. DOI: 10.3390/antiox13070841.

References

Chauvin M, Garambois V, Colombo P, Chentouf M, Gros L, Brouillet J . Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells. Sci Rep. 2021; 11(1):2231. PMC: 7838181. DOI: 10.1038/s41598-021-81819-y. View

Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View

Yung Y, Stoddard N, Chun J . LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014; 55(7):1192-214. PMC: 4076099. DOI: 10.1194/jlr.R046458. View

. Lead and lead compounds. IARC Monogr Eval Carcinog Risk Chem Hum. 1980; 23:325-415. View

Liu L, Chen J, Liu C, Luo Y, Chen J, Fu Y . Relationships Between Biological Heavy Metals and Breast Cancer: A Systematic Review and Meta-Analysis. Front Nutr. 2022; 9:838762. PMC: 9245072. DOI: 10.3389/fnut.2022.838762. View

Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E . Surgical management of BRCA-mutation carriers: A single institution experience. Eur J Surg Oncol. 2022; 48(8):1706-1712. DOI: 10.1016/j.ejso.2022.04.024. View

Siddiqui M, Jyoti , Singh S, Mehrotra P, Singh K, Sarangi R . Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study. Environ Int. 2006; 32(5):630-7. DOI: 10.1016/j.envint.2006.02.002. View

Li S, Silvestri V, Leslie G, Rebbeck T, Neuhausen S, Hopper J . Cancer Risks Associated With and Pathogenic Variants. J Clin Oncol. 2022; 40(14):1529-1541. PMC: 9084432. DOI: 10.1200/JCO.21.02112. View

Marciniak W, Matousek T, Domchek S, Angelo Paradiso , Patruno M, Irmejs A . Blood Arsenic Levels as a Marker of Breast Cancer Risk among Carriers. Cancers (Basel). 2021; 13(13). PMC: 8269342. DOI: 10.3390/cancers13133345. View

10.

Anttila A, Uuksulainen S, Rantanen M, Sallmen M . Lung cancer incidence among workers biologically monitored for occupational exposure to lead: a cohort study. Scand J Work Environ Health. 2022; 48(7):540-548. PMC: 10539111. DOI: 10.5271/sjweh.4046. View

11.

Benderli Cihan Y, Sozen S, Yildirim S . Trace elements and heavy metals in hair of stage III breast cancer patients. Biol Trace Elem Res. 2011; 144(1-3):360-79. DOI: 10.1007/s12011-011-9104-z. View

12.

Michalczyk K, Kupnicka P, Witczak G, Tousty P, Bosiacki M, Kurzawski M . Assessment of Cadmium (Cd) and Lead (Pb) Blood Concentration on the Risk of Endometrial Cancer. Biology (Basel). 2023; 12(5). PMC: 10215627. DOI: 10.3390/biology12050717. View

13.

. Inorganic and organic lead compounds. IARC Monogr Eval Carcinog Risks Hum. 2006; 87:1-471. PMC: 4781642. View

14.

Fu H, Boffetta P . Cancer and occupational exposure to inorganic lead compounds: a meta-analysis of published data. Occup Environ Med. 1995; 52(2):73-81. PMC: 1128158. DOI: 10.1136/oem.52.2.73. View

15.

Friebel T, Domchek S, Rebbeck T . Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju091. PMC: 4081625. DOI: 10.1093/jnci/dju091. View

16.

Steenland K, Barry V, Anttila A, Sallmen M, Mueller W, Ritchie P . Cancer incidence among workers with blood lead measurements in two countries. Occup Environ Med. 2019; 76(9):603-610. DOI: 10.1136/oemed-2019-105786. View

17.

Kastora S, Triantafyllidou O, Kolovos G, Kastoras A, Sigalos G, Vlahos N . Combinational approach of retrospective clinical evidence and transcriptomics highlight AMH superiority to FSH, as successful ICSI outcome predictor. J Assist Reprod Genet. 2020; 37(7):1623-1635. PMC: 7376803. DOI: 10.1007/s10815-020-01802-w. View

18.

Steenland K, Boffetta P . Lead and cancer in humans: where are we now?. Am J Ind Med. 2000; 38(3):295-9. DOI: 10.1002/1097-0274(200009)38:3<295::aid-ajim8>3.0.co;2-l. View

19.

Gaudet M, Deubler E, Kelly R, Diver W, Teras L, Hodge J . Blood levels of cadmium and lead in relation to breast cancer risk in three prospective cohorts. Int J Cancer. 2018; 144(5):1010-1016. PMC: 7063440. DOI: 10.1002/ijc.31805. View